{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:42:08Z","timestamp":1777138928689,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s43441-026-00933-z","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:52:07Z","timestamp":1770825127000},"page":"654-657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ensuring Integrity of the Medicaid Drug Rebate Program"],"prefix":"10.1007","volume":"60","author":[{"given":"Priyanka A.","family":"Abraham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph T.","family":"Kannarkat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin N.","family":"Rome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan J.","family":"Darrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"933_CR1","unstructured":"Williams E, Rudowitz R, Bell C. Recent Trends in Medicaid Outpatient Prescription Drugs and Spending. KFF. 2024. https:\/\/www.kff.org\/medicaid\/recent-trends-in-medicaid-outpatient-prescription-drugs-and-spending\/. Accessed Dec 9 2025."},{"key":"933_CR2","unstructured":"Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program. Federal Register. 2025. https:\/\/www.federalregister.gov\/documents\/2024\/09\/26\/2024-21254\/medicaid-program-misclassification-of-drugs-program-administration-and-program-integrity-updates. Accessed Mar 29 2025."},{"key":"933_CR3","unstructured":"Lowering Drug Prices by Once Again Putting Americans First. The White House. 2025. https:\/\/www.whitehouse.gov\/presidential-actions\/2025\/04\/lowering-drug-prices-by-once-again-putting-americans-first\/. Accessed Apr 18 2025."},{"key":"933_CR4","unstructured":"Dolan R. Understanding the Medicaid Prescription Drug Rebate Program. 2025. https:\/\/www.kff.org\/medicaid\/issue-brief\/understanding-the-medicaid-prescription-drug-rebate-program\/. Accessed Apr 17 2025."},{"key":"933_CR5","unstructured":"Potential Misclassifications Reported by Drug Manufacturers May Have Led To $1 Billion In Lost Medicaid Rebates. U.S. Department of Health and Human Services, Office of Inspector General; 2017. https:\/\/oig.hhs.gov\/documents\/evaluation\/2787\/OEI-03-17-00100-Complete%20Report.pdf. Accessed Dec 9 2025."},{"key":"933_CR6","unstructured":"United States Ex Rel. Coffman v. Mylan Inc. and Mylan Specialty L.P.(U.S. Department of Justice 2017). 2017. https:\/\/www.justice.gov\/d9\/press-releases\/attachments\/2017\/08\/17\/mylan_settlement_agreement_0.pdf. Accessed Dec 18 2025."},{"key":"933_CR7","unstructured":"Severin S. Medicare Medicaid Drug Rebate Programs | Whistleblower Law. Whistleblower Law Collaborative. 2024. https:\/\/www.whistleblowerllc.com\/medicare-medicaid-drug-rebate\/. Accessed December 9, 2025."},{"key":"933_CR8","unstructured":"U.S. Department of Health and Human Services. Medicaid Services Investment and Accountability Act of 2019 Preventing the Misclassification of Drugs Under the Medicaid Drug Rebate Program Federal Fiscal Year 2024. 2025. https:\/\/www.medicaid.gov\/prescription-drugs\/downloads\/mdrp-misclassification-rtc.pdf. Accessed Dec 9 2025."},{"key":"933_CR9","unstructured":"MACStats Medicaid, Data Book CHIP, Payment CHIP, and Access Commission. 2015. https:\/\/www.macpac.gov\/wp-content\/uploads\/2020\/07\/MACStats-Medicaid-and-CHIP-Data-Book-December-2015.pdf. Accessed Dec 9 2025."},{"key":"933_CR10","unstructured":"MACStats, Payment CHIP, and Access Commission. 2023. https:\/\/www.macpac.gov\/wp-content\/uploads\/2023\/12\/MACSTATS_Dec2023_WEB-508.pdf. Accessed Dec 9 2025."},{"key":"933_CR11","unstructured":"Reasonable Assumptions in Manufacturer Reporting of AMPs and Best Prices. U.S. Department of Health and Human Services, Office of Inspector General. 2019. Accessed December 9, 2025. https:\/\/oig.hhs.gov\/oei\/reports\/oei-12-17-00130.pdf. Accessed Dec 9 2025."},{"key":"933_CR12","unstructured":"United States Ex Rel. Deborah Sheldon v. Allergan Sales, LLC. 49 F.4th 873, 873 (US Court of Appeals for the Fourth Circuit 2022). https:\/\/www.ca4.uscourts.gov\/opinions\/202330.P.pdf."},{"key":"933_CR13","unstructured":"Federal Court Clarifies Medicaid Rebate Reporting Requirements for New Strengths. 2025. https:\/\/www.sidley.com\/en\/insights\/newsupdates\/2025\/05\/federal-court-clarifies-medicaid-rebate-reporting-requirements-for-new-strengths. Accessed Dec 9 2025."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00933-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00933-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00933-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:26:20Z","timestamp":1777137980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00933-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00933-z","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Priyanka A. Abraham receives personal fees from McKesson Corporation outside the submitted work. Dr. Rome reports research grants from Humana, the Elevance Health Public Policy Institute, and the PCMA Foundation, and personal fees from Alosa Health. All other authors declare no financial or non-financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}